RecruitingPhase 2NCT06003270

Biological Effects of Quercetin in COPD Phase II

Effects of Quercetin on the Oxidative Stress and Inflammatory Markers in COPD Phase II


Sponsor

Temple University

Enrollment

30 participants

Start Date

Nov 1, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

This study determines whether quercetin supplementation reduces the inflammation and oxidative stress markers in patients with chronic obstructive pulmonary disease. It is small study with 8 subjects receiving quercetin 1000 mg/day, 8 patients receiving 500 mg/day and 4 subjects receive placebo.


Eligibility

Min Age: 40 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether quercetin — a natural compound found in fruits and vegetables — can reduce inflammation in people with chronic obstructive pulmonary disease (COPD), a lung condition that makes it hard to breathe. **You may be eligible if:** - You are between 40 and 80 years old - You have been diagnosed with COPD - You are a current or former smoker with at least 10 pack-years of smoking history - Your lung function tests show moderate COPD **You may NOT be eligible if:** - You are allergic to quercetin - Your primary diagnosis is asthma (not COPD) - You had a respiratory infection or were hospitalized in the past month - You take warfarin or cyclosporine - You consume more than 150 mg of quercetin daily from food or supplements - You have inflammatory bowel disease or a history of lung cancer - You are pregnant, nursing, or of childbearing age and unwilling to use contraception Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGQuercetin 1000 mg

Active comparator

DRUGQuercetin 500 MG

Active comparator

DRUGPlacebo

Placebo comparator


Locations(1)

Nathaniel Marchetti

Philadelphia, Pennsylvania, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06003270


Related Trials